Interpace Biosciences (Interpace Biosciences) Cash-to-Debt : 0.31 (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Interpace Biosciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.31.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Interpace Biosciences couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Interpace Biosciences's Cash-to-Debt or its related term are showing as below:

IDXG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.46 Max: No Debt
Current: 0.31

During the past 13 years, Interpace Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.08. And the median was 0.46.

IDXG's Cash-to-Debt is ranked worse than
75.21% of 234 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.435 vs IDXG: 0.31

Interpace Biosciences Cash-to-Debt Historical Data

The historical data trend for Interpace Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Interpace Biosciences Cash-to-Debt Chart

Interpace Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.33

0.58

0.25

0.30

0.31

Interpace Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.30	0.36	0.34	0.37	0.31

Competitive Comparison of Interpace Biosciences's Cash-to-Debt

For the Diagnostics & Research subindustry, Interpace Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Interpace Biosciences's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Cash-to-Debt falls into.

Interpace Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Interpace Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.498	/	(5.477	+	5.715)
	=	0.31

Interpace Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.498	/	(5.477	+	5.715)
	=	0.31

Interpace Biosciences (OTCPK:IDXG) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Interpace Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Interpace Biosciences (Interpace Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PF42:Germany

Address

300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Executives

Christopher Mccarthy	officer: Principal Financial Officer	C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal	director	2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell	director, officer: President and CEO	1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin	10 percent owner	2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel	officer: Chief Financial Officer	REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca	director	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan	director	C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p.	10 percent owner	2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy	director	2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership	10 percent owner	55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev	director, 10 percent owner	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg	officer: Chief Accounting Officer	INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard	officer: Chief Commerical Officer	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054